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Table 2
IFI (EORTC/MSG Criteria)
UPN Symptoms Imaging BAL IFI
27 Yes Ground glass opacity/
consolidation
Galactomannan
+ve
Probable
46 Yes New focal opacity in
previous consolidation
-ve Possible
85 Yes Small b/l pleural effusion
with ground glass opacity
and septal thickening
-ve Possible
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One patient developed oral candidiasis treated with mica-
fungin. One patient had splenic leisons (presumed fungal)
treated with treatment dose posaconazole and improved.
None of these patients had aGVHD at time of IFI diagnosis.
None of these patients died of fungal related causes. 4 out of
5 patients were alive at last follow up. One died of relapse.
Conclusion: Micafungin followed by posaconazole is effec-
tive as primary IFI prophylaxis in unrelated donor HCT.
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Nocardial infection is emerging as an important cause of
morbidity and mortality among hematopoietic stem cell
transplant (HSCT) recipients. Risk factors and outcomes in
this population remain undeﬁned.
We performed a matched case-control study (1:2 ratio).
Cases were deﬁned as recipients of allogeneic HSCT with
a microbiological diagnosis of nocardial infection. Control
subjects were matched for age, timing and transplant type.
Between January 2007 and December 2011, among 440
allogeneic HSCT recipients, 11 (0.03%) were diagnosed with
nocardiosis.
Infection occurred at a median of 510 days (range 139-
1042) after HSCT and was disseminated in 45% of cases.
Diagnoses clustered in the fall (68%). Pulmonary involvement
with nodular inﬁltrates occurred in 91% of cases. Final culture
results were available 55.7 days after diagnostic testing
(range 14-120 days). Nocardia nova was the strain most
commonly isolated (27%). Co-infection with S.aureus, Pseu-
domonas, CMV and Mycobacterium sp. occurred in 73% of all
cases. Trimetroprim-Sulfametoxazole was not protective in 4
out of 11 patients (36%) receiving it for Pneumocystis jirovecii
pneumonia prophylaxis.
In univariate analysis, chronic GVHD (P¼ .011) was asso-
ciated with nocardial infection. Other associated conditions
included bronchiolitis obliterans syndrome (BOS) (P¼ .033),
steroid-induced diabetes mellitus (p¼< .001), and opportu-
nistic infection within the preceding 6 months (p¼ < .001).
Positive CMV serologic status or recent CMV infection were
not signiﬁcant variables. High-dose corticosteroid treatment
within the preceding 6 months (P¼ .005), tacrolimus therapy
(P¼ .002), antifungal prophylaxis (p ¼ <.001), prior autolo-
gous transplant (P¼ .008), and rituximab treatment within12 months (p ¼ < .001) were speciﬁcally associated with
nocardiosis. Patients with Nocardia infection had signiﬁ-
cantly higher mean tacrolimus levels (p ¼ .043), LDH levels
(p ¼ .040), and neutrophil counts (p¼ .002) than controls.
Nocardial infection is an infrequent delayed complication
of allogeneic HSCT primarily affecting recipients with chronic
GVHD. This has biologic correlation, since these patients often
require prolonged immunosuppressive therapies, targeting
both B and T cells, and may have underlying anatomic factors
interferingwithmicrobial clearance, such as bronchiectasis in
BOS. High-dose corticosteroid treatment and its conse-
quences, notably steroid-induced DMII, may increase
susceptibility to this infection. Nocardiosis should be
promptly considered and carefully investigated in susceptible
cGVHD patients, given its adverse impact on prognosis, as
demonstrated by the signiﬁcant reduction in the overall
survival of the infected cohort (72.7% vs 100%, P¼ .013).341
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The Rh D antigen is one of the most immunogenic red
blood cell antigens know. Despite this, it is not considered in
matching schemes for hematopoietic progenitor cell (HPC)
transplants. The frequency of anti-D after Rh mismatched
allogeneic HPC transplants is reportedly low. The objective of
this study was to retrospectively study Rh mismatched HPC
transplants and examine both allogeneic anti-D formation as
well as transplant outcome measures. From January 1999 to
April 2011, 104 consecutive adult Rh mismatched HPC
transplants were performed at our institution and were
available for review. We compared transplants with Rh+
recipients with Rh- donors (R+/D-, n¼60) to those with Rh-
recipients and Rh+ donors (R-/D+, n+44). There was no
difference in underlying diagnoses, graft source, dose of HPC,
degree of HLA matching, conditioning, or type of graft versus
host disease (GVHD) prophylaxis. The median follow-up was
655.5 days (range 14 e 4264 days). Only 2 patients formed
anti-D during the follow-up period, and both were in the R+/
D- group of transplants. One was never exposed to Rh-
positive blood products. The second patient was exposed to
multiple Rh-positive apheresis platelet products prior to
antibody formation. Ten patients formed other red cell allo-
antibodies with no statistical difference between groups. The
most common antibody formedwas anti-E. The overall use of
rbc's and platelets post transplant was similar in both groups,
although the use of Rh-positive rbc's was more common in
the R+/D- group pre-transplant, and the R-/D+ group post-
transplant. A low incidence of chronic GVHD was seen in
both groups (82% of R+/D- transplants had no chronic GVHD,
64% of R-/D+ transplants had no chronic GVHD, P ¼ .045). No
difference in platelet and neutrophil engraftment was
demonstrated.342
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Allogeneic unrelated hematopoietic stem cell transplants
(HSCT) are complex procedures that need adequate hospital
infrastructure, a competent team, high-cost procedures and
medications. Most transplants that are performed in Brazil
are paid by the government. The national health system
reimburses the hospital U$ 35,801.00 as a ﬂat rate. The
government has recently increased this amount by 60% but
there are not national studies to use to evaluate the appro-
priateness of this amount. The objective of this study was to
retrospectively evaluate the cost of ten consecutive unrelated
donor HSCT performed in our institution.
Methods: Theprojectwas approved byour IRB (CEP-UNIFESP
#1875/11) and granted waiver to request consent. The costs
wereevaluated fromtheﬁrst appointmentuntil oneyear after
transplant or death divided as 1) pre-HSCT, 2) conditioning
therapy, 3) from the day of transplant until ﬁrst discharge, 4)
until D+100, 5) until D+180, and 6) until D+360. The costs
included medications, supplies, blood transfusions, labora-
tory, imaging and the cost of the ward. Housing and out-of
pocket costs or loss of income were not evaluated. Patients
were scored 1 to 3 according to the Pediatric EBMT score.
Results: Ten consecutive children 2-14 years of age under-
went unrelated donor HSCT from June, 2010 to May, 2011.
Diagnoses were ALL (4). AML (3), lymphoma (2), and aplastic
anemia (1). Three patients had early disease and others were
in advanced phases of the disease. Eight were CMV positive.
Five hadmarrow and ﬁve cord blood transplants. Themedian
interval to transplant was 3.7 years from diagnosis and 80
days from referral. The patients remained hospitalized for
a median of 80 days (21-50). Median time to engraftment
was D+22 (12-56) and six had complications and needed
Intensive Care support. Of the 10 children, seven were dis-
charged but three eventually relapsed and died, overall
survival is 50%. The median total cost during the ﬁrst year
was U$118,908.00 (mean U$ 139,861.00) e 44% of that spent
within the ﬁrst 100 days post HSCT. The ﬁrst admission had
a median total cost of U$ 64,385.00 (14,400 e 166,792). Total
costs were approximately 40% higher than the direct cost.
The highest costs were blood products and medications. No
relationship was found between cost and age, gender, graft
source of Pediatric EBMT-score.
Conclusion: Unrelated-donor HSCT is an expensive proce-
dure and the government only partially reimburses its cost.
Even with a 60% increase in reimbursement there will be
a deﬁcit in more than half of the procedures. We are working
to increase the amount paid for speciﬁc complications and
will have to continue to ﬁnd alternative resources to pay for
the transplants.343
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Materials and Methods: We retrospectively reviewed 76
medical records of patients older than 50 years receiving an
allogeneic HSCT in our centers. We evaluated the following
characteristics: sex, age, diagnosis, stage, comorbidities
(according to the HCT-CI score), type of donor, histocom-
patibility, conditioning and immunosupression. We analyzed
the incidence and severity of Graft-vs-Host disease (GVHD)
and treatment related mortality (TRM) with Chi Square and
Overall Survival (OS) and Disease Free Survival (DFS) with
Kaplan Meier. For multivariate analysis (MA) we used Cox
regression model for time dependant outcomes and logistic
regression for dichotomic variables, considering signiﬁcant
a P < .05.
Results: Between March 1998 and June 2012, 76 transplants
were performed with a median follow up of 1.9 years.
Fourteen patients were older than 60 years, 51 were male,
HCT-CI score was 0 (41%), 1 (36%), 2 (23%), common diag-
nosis were AML (35%), MDS (30%) and MPN (20%), 65% were
in late stage, 80% received a transplant from a MRD, 37%
received FluMel conditioning regimen, 32% FluBu and 12%
BuCy, 66% received tacrolimus (Fk) based regimen and 34%
cyclosporine. Acute GVHD (aGVHD) incidencewas 51%, aGVH
grade II-IV 29%. AML patients had a lower incidence of
aGVHD (36% vs. 61%, P < .03) still signiﬁcant in MA (HR 0.27;
95% CI 0.07-0.98;P¼ .04) as well as FluMel conditioning (33%
vs. 59%,P¼ .02), in contrast to unrelated donor (URD) (aGVHD
GII-IV 53% vs. 23%,P¼ .02). Chronic GVHD incidence was 33%,
extensive in 10%. Early TRM (day 100) was 17% and global
30%. Female patients had lower early TRM (4% vs. 25%,P ¼
.02) opposite to HCT-CI score 2 patients that experienced
a higher global TRM (58% vs. 26%, P < .04) still signiﬁcant in
MA (HR 4.6; 95% CI 1.03-20.9;P¼ .04) as well as MPN patients
(64% vs. 25%, P < .01) also signiﬁcant in MA (HR 7.2; 95% CI
1.20-43.7;P ¼ .03). OS was 43% (1 year) and 20% (3 years).
Patients older than 60 had a higher OS (1/3 years 61/43% vs.
38/14%;P ¼ .01), while FluBu was associated to a lower OS (1/
3 years 25/10% vs. 49/23%, P < .05), not signiﬁcant in MA.
Regarding immunosuppressant, the use of Fk was associated
with a higher OS (1/3 years 44/20% vs. 19/6%, P < .01)
signiﬁcant in MA (HR 0.45; 95% CI 0.2-0.9;P ¼ .04) and DFS
(1/3 years 33/18% vs. 11/5%,P ¼ .01).
Conclusion: According to the literature, URD is associated
with a higher incidence of clinical signiﬁcant aGVHD (P¼ .02)
and FluMel presented lower incidence of aGVHD as well as
AML patients. Regarding TRM female patients had a lower
early TRM and lower HCT-CI score had lower global TRM.
FluBu was associated with a lower OS, while Fk patients had
a higher OS and DFS. Interestingly patients older than 60 had
higher OS not signiﬁcant in MA, probably due to a better
selection: none had HCT-CI higher than 1, only 1 patient
received an URD transplant, most of them received Fk base
immunosuppressant and all of them received a NMA trans-
plant.344
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